Abstract
Cholangiocarcinoma (CC) is the second most common malignant disease of the liver. In recent decades various methods of treatment have been introduced. Nevertheless the number of treatment options for СС is still limited. Gemcitabine and cisplatin are the standard treatment for patients with inoperable CC. The second line of chemotherapy has not yet been standardized and depends on the interaction with first-line therapy. In addition many bile cancer studies to date cannot evaluate the differential activity of therapy of different anatomical localizations along the bile tract. There is no reliable evidence of the effectiveness of adjuvant therapy. The correlation of survival increase in patients with worse prognosis when using adjuvant therapy after surgical intervention seems to be reliable. The study of the molecular profile led to a more complex understanding of the genetic changes leading to clinically expressed malignant neoplasms and the possible future differentiation by anatomical or molecular structure would be optimal for the selection of chemotherapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
